Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCG + autologous tumor cell vaccine
- Development stage
- Unknown
- Lead developer
- Vaccinogen
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
A combination immunotherapy consisting of viable, metabolically active autologous tumor cells (derived from the patient's own resected cancer) mixed with bacillus Calmette-Guérin (BCG), an immunomodulatory agent. This personalized cancer vaccine is designed to stimulate the patient’s immune system to recognize and attack residual or recurring cancer cells after primary treatment such as surgery. The mechanism involves presenting a broad array of patient-specific tumor antigens in conjunction with BCG, which acts as an adjuvant to enhance immune activation. OncoVAX is a notable example developed for colon cancer and has shown significant benefit in reducing recurrence and improving survival in Stage II colon cancer patients[1][6][8]. Preclinical studies have also explored similar formulations for other cancers such as breast cancer[4].
- Brand names
- OncoVAX
- Other names
- autologous tumor cells/bacillus Calmette-Guérin/formalin-based vaccineautologous tumor cell-BCG vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on BCG + autologous tumor cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCG + autologous tumor cell vaccine.